NIKTIMVO™ (axatilimab-csfr) injection, for intravenous use NOW APPROVED a new strategy for treating cGVHD
Niktimvo™ (axatilimab-csfr) is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.1
NIKTIMVO™ (axatilimab-csfr) injection, for intravenous use NOW APPROVED a new strategy for treating cGVHD
Niktimvo™ (axatilimab-csfr) is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.1
